Polymorphisms in NAT2 gene and atherosclerosis in an Algerian population

Arch Med Res. 2010 Apr;41(3):215-20. doi: 10.1016/j.arcmed.2010.03.008.

Abstract

Background and aims: The etiology of atherosclerosis is multifactorial. Genetic and environmental factors are involved in the development of atherosclerosis. Human arylamine N-acetyltransferase 2 (NAT2) is an important metabolizing enzyme that exhibits genetic polymorphisms and modifies individual response and/or toxicity to many xenobiotics. We undertook this study to investigate the NAT2 polymorphisms in patients with atherosclerosis.

Methods: Genotyping for NAT2 alleles was performed using polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) in 285 Algerian patients with atherosclerosis and 286 controls.

Results: There was no association between NAT2 polymorphisms and atherosclerosis risk. However, the haplotype NAT2(*)5F decreased susceptibility to the disease (p = 0.005, OR = 0.55, 95% CI = 0.37-0.84). The frequency of the slow acetylator phenotype was approximately 50% in both cases and controls.

Conclusions: These results suggest that NAT2 polymorphisms may not be involved in the pathogenesis of atherosclerosis.

MeSH terms

  • Adult
  • Algeria
  • Arylamine N-Acetyltransferase / genetics*
  • Arylamine N-Acetyltransferase / metabolism
  • Atherosclerosis / enzymology*
  • Atherosclerosis / genetics*
  • Base Sequence
  • Case-Control Studies
  • DNA Primers / genetics
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Haplotypes
  • Humans
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Polymorphism, Genetic*
  • Polymorphism, Restriction Fragment Length
  • Risk Factors

Substances

  • DNA Primers
  • Arylamine N-Acetyltransferase
  • NAT2 protein, human